# INTERNATIONAL STANDARD

Third edition 2020-09

Sterilization of health care products — Liquid chemical sterilizing agents for single-use medical devices utilizing animal tissues and their derivatives — Requirements for characterization, development, validation and routine control of a sterilization process for medical devices

Stérilisation des produits de santé — Agents stérilisants chimiques liquides pour dispositifs médicaux non réutilisables utilisant des tissus animaux et leurs dérivés — Exigences pour la caractérisation, le développement, la validation et le contrôle de routine d'un procédé de stérilisation de dispositifs médicaux



Reference number ISO 14160:2020(E)



#### **COPYRIGHT PROTECTED DOCUMENT**

© ISO 2020

All rights reserved. Unless otherwise specified, or required in the context of its implementation, no part of this publication may be reproduced or utilized otherwise in any form or by any means, electronic or mechanical, including photocopying, or posting on the internet or an intranet, without prior written permission. Permission can be requested from either ISO at the address below or ISO's member body in the country of the requester.

ISO copyright office CP 401 • Ch. de Blandonnet 8 CH-1214 Vernier, Geneva Phone: +41 22 749 01 11 Email: copyright@iso.org Website: www.iso.org

Published in Switzerland

Page

# Contents

Foreword				
Introduction				
1	-	c.		
2	Normative references			
3	Terms and definitions			
4		eneral		
5	Sterilizing agent characterization			
		eneral erilizing agent		
		icrobicidal effectiveness		
		fects on materials		
		Ifety and the environment		
6	Process and equipment characterization		8	
		eneral		
		ocess characterization		
		quipment characterization		
7		Product definition		
8		definition		
	8.1 Pi	irpose	10	
		etermination of the inactivation kinetics		
		ethod for neutralization Ifety quality and performance		
9	Validation       9.1     General			
		stallation qualification		
		2.1 Equipment		
	9.	2.2 Installation		
		perational qualification		
		erformance qualification		
		4.1 General		
		<ul> <li>4.2 Microbiological performance qualification (MPQ)</li> <li>4.3 Physical performance qualification</li></ul>	13 1 <i>1</i> .	
		4.4 Aseptic processing qualification		
		eview and approval of validation		
10	Routine	monitoring and control		
11		release from sterilization		
12	Maintaining process effectiveness			
		eneral		
		aintenance of equipment		
	12.3       Requalification         12.4       Assessment of change			
			18	
Annex	Annex A (informative) Guidance for the application of this document			
Annex B (normative) Determination of lethal rate of the sterilization process			31	
Annex C (informative) Flowchart for microbicidal effectiveness (see 5.3), process definition (see Clause 8), and microbiological performance qualification (see 9.4.2)			35	
Biblio	Bibliography			
	-			

### Foreword

ISO (the International Organization for Standardization) is a worldwide federation of national standards bodies (ISO member bodies). The work of preparing International Standards is normally carried out through ISO technical committees. Each member body interested in a subject for which a technical committee has been established has the right to be represented on that committee. International organizations, governmental and non-governmental, in liaison with ISO, also take part in the work. ISO collaborates closely with the International Electrotechnical Commission (IEC) on all matters of electrotechnical standardization.

The procedures used to develop this document and those intended for its further maintenance are described in the ISO/IEC Directives, Part 1. In particular, the different approval criteria needed for the different types of ISO documents should be noted. This document was drafted in accordance with the editorial rules of the ISO/IEC Directives, Part 2 (see <a href="https://www.iso.org/directives">www.iso.org/directives</a>).

Attention is drawn to the possibility that some of the elements of this document may be the subject of patent rights. ISO shall not be held responsible for identifying any or all such patent rights. Details of any patent rights identified during the development of the document will be in the Introduction and/or on the ISO list of patent declarations received (see <a href="https://www.iso.org/patents">www.iso.org/patents</a>).

Any trade name used in this document is information given for the convenience of users and does not constitute an endorsement.

For an explanation of the voluntary nature of standards, the meaning of ISO specific terms and expressions related to conformity assessment, as well as information about ISO's adherence to the World Trade Organization (WTO) principles in the Technical Barriers to Trade (TBT), see <a href="https://www.iso.org/iso/foreword.html">www.iso.org/iso/foreword.html</a>.

This document was prepared by Technical Committee ISO/TC 198, *Sterilization of health care products*, in collaboration with the European Committee for Standardization (CEN) Technical Committee CEN/TC 204, *Sterilization of medical devices*, in accordance with the Agreement on technical cooperation between ISO and CEN (Vienna Agreement).

This third edition cancels and replaces the second edition (ISO 14160:2011), which has been technically revised.

The main changes compared to the previous edition are as follows:

- aligned definitions with those used in other standards for development, validation and routine control of sterilization processes and added new definitions;
- incorporated defined terms consistently throughout the document;
- updated cross-references;
- revised informative <u>Annex A</u> to follow the order of the normative body of the standard;
- added clarification to normative <u>Annex B</u> in regard to applying the overkill approach.

Any feedback or questions on this document should be directed to the user's national standards body. A complete listing of these bodies can be found at <u>www.iso.org/members.html</u>.

### Introduction

A sterile medical device is one that is free of viable microorganisms. International standards which specify requirements for validation and routine control of sterilization processes require, when it is necessary to supply a sterile medical device, that adventitious microbiological contamination of a medical device prior to sterilization be minimized. Even so, medical devices produced under standard manufacturing conditions in accordance with the requirements for quality management systems (see for example, ISO 13485) have microorganisms on them prior to sterilization, albeit in low numbers. The purpose of sterilization is to inactivate the microbiological contaminants and thereby transform the non-sterile medical devices into sterile ones.

The kinetics of inactivation of a pure culture of microorganisms by physical and/or chemical agents used to sterilize medical devices can generally best be described by an exponential relationship between the numbers of microorganisms surviving and the extent of treatment with the sterilizing agent; inevitably this means that there is always a finite probability that a microorganism survives regardless of the extent of treatment applied. For a given treatment, the probability of survival is determined by the number and resistance of microorganisms and by the environment in which the organisms exist during treatment. It follows that the sterility of any one medical device in a population of items subjected to sterilization processing cannot be guaranteed and the sterility of a processed population is defined in terms of the probability of there being a viable microorganism present on a medical device.

Attention also has to be given to a number of factors, including the microbiological status (bioburden) of incoming raw materials and/or components and their subsequent storage, and to the control of the environment in which the product is manufactured, assembled and packaged (see also ISO 13485).

Requirements for quality management systems for medical device production are given in ISO 13485. The standards for quality management systems recognize that for certain processes used in manufacturing, the effectiveness of the process cannot be fully verified by subsequent inspection and testing of the product. Sterilization is an example of such a process. For this reason, sterilization processes are validated for use, the performance of the sterilization process is monitored routinely, and the equipment is maintained.

Animal tissues and their derivatives are used as constituents of certain medical devices to provide performance characteristics that present advantages over the characteristics provided by non-animalbased materials. The range and quantities of materials of animal origin in medical devices vary; such materials can comprise a major part of the device, can be a product coating or impregnation, or can be used in the manufacturing process for the medical device.

This document describes requirements that, if met, will provide a liquid chemical sterilization process that has appropriate microbicidal activity for single-use medical devices containing materials of animal origin or their derivatives. The sterilizing agents used most frequently for medical devices are moist heat, dry heat, irradiation and ethylene oxide. While some devices containing animal tissues can be compatible with these commonly applied methods of sterilization (historically, for example, catgut sutures have been sterilized by irradiation), other devices, such as biological heart valves or tissue patches, are not compatible with conventional sterilization processes. It has been recognized that other sterilizing agents could have to be used in these exceptional circumstances. Liquid chemical sterilization is normally chosen over other sterilization processes in order that the medical devices present the desired physical properties of the tissue after sterilization. Sterilization by liquid chemicals of medical devices made in whole or in part from tissues of animal origin represents a special case in terms of establishing an effective sterilization process. In common with the other sterilization methods, the efficacy of a liquid chemical sterilization process needs to be demonstrated and recorded before it is adopted for routine use.

Liquid chemical sterilization requires determination of types of microorganisms comprising the bioburden and their resistance to the sterilization process in order to establish the appropriate reference microorganism, whether that be a recognized biological indicator or an isolate from the bioburden. Compliance with the requirements of this document ensures that the microbicidal activity of the liquid chemical sterilization process is both reliable and reproducible so that predictions can be made, with reasonable confidence, that there is a low level of probability of there being a viable

microorganism present on a product after sterilization. Specification of this probability is a matter for regulatory authorities and can vary among regions or countries (see for example, EN 556-1 and ANSI/ AAMI ST67).

Exposure to a properly validated, accurately controlled sterilization process is not the only factor associated with the provision of reliable assurance that the product is sterile and, in this regard, suitable for its intended use. Attention is therefore given to a number of considerations including:

- a) the source and harvesting conditions of the tissue;
- b) the microbiological status of incoming raw materials or components, or both;
- c) the routine control of any cleaning and disinfection procedures used on the product;
- d) the control of the environment in which the product is manufactured, assembled and packaged;
- e) the control of equipment and processes;
- f) the control of personnel and their hygiene;
- g) the manner and materials in which the product is packaged; and
- h) the conditions under which product is stored.

## Sterilization of health care products — Liquid chemical sterilizing agents for single-use medical devices utilizing animal tissues and their derivatives — Requirements for characterization, development, validation and routine control of a sterilization process for medical devices

#### 1 Scope

This document specifies requirements for the characterization of a liquid chemical sterilizing agent and for the development, validation, process control and monitoring of sterilization by liquid chemical sterilizing agents of single-use medical devices comprising, in whole or in part, materials of animal origin.

This document covers the control of risks arising from contamination with bacteria and fungi by application of a liquid chemical sterilization process. Risks associated with other microorganisms can be assessed using other methods (see NOTE 1).

This document is not applicable to material of human origin.

This document does not describe methods for the validation of the inactivation of viruses and transmissible spongiform encephalopathy (TSE) agents (see NOTE 2 and NOTE 3).

This document does not describe methods for validation of the inactivation or elimination of protozoa and parasites.

The requirements for validation and routine control described in this document are only applicable to the defined sterilization process of a medical device, which is performed after the manufacturing process, and do not take account of the lethal effects of other bioburden reduction steps (see NOTE 4).

This document does not specify tests to establish the effects of any chosen sterilization process upon the fitness for use of the medical device (see NOTE 5).

This document does not cover the level of residual sterilizing agent within medical devices (see NOTE 6).

Guidance for the characterization of a liquid chemical sterilizing agent and for the development, validation, process control and monitoring of sterilization by liquid chemical sterilizing agents of single-use medical devices comprising, in whole or in part, materials of animal origin is provided in informative <u>Annex A</u>.

NOTE 1 The prior application of risk management principles to medical devices utilizing animal tissues, as described in ISO 22442-1 is important. ISO 18362 provides information on control of microbial risks during processing of cell-based health-care products.

NOTE 2 Liquid chemical sterilizing agents traditionally employed to sterilize animal tissues in medical devices might not be effective in inactivating the causative agents of TSE such as bovine spongiform encephalopathy (BSE), or scrapie. Satisfactory validation in accordance with this document does not necessarily demonstrate inactivation of infective agents of this type. Risk controls related to sourcing, collection and handling of animal materials are described in ISO 22442-2.

NOTE 3 The validation of the inactivation, elimination, or elimination and inactivation of viruses and TSE agents is described in ISO 22442-3.

NOTE 4 Manufacturing processes for medical devices containing animal tissues frequently include exposure to chemical agents which can significantly reduce the bioburden on the medical device. Following the manufacturing process, a medical device is exposed to a specified sterilization process.

NOTE 5 Such testing is a crucial part of the design and development of a medical device.